Second Parkinson’s Group in Phase 1 Trial Receives ISCO’s Neural Stem Cell Therapy – Parkinson’s News Today
Parkinson’s News Today |
Second Parkinson’s Group in Phase 1 Trial Receives ISCO’s Neural Stem Cell Therapy
Parkinson’s News Today A second group of Parkinson’s patients in a Phase 1 clinical trial have received International Stem Cell Corporation’s neural stem cell therapy. The main goal of the trial (NCT02452723) at Royal Melbourne Hospital is to see whether ISCO’s stem cell … |
Drug Target Review |
CRISPR/Cas9 technique suppresses malaria infection in mosquitos
Drug Target Review Using a gene-editing technique known as CRISPR/Cas9, scientists have shown that inactivating the gene FREP1 reduces mosquitos’ susceptibility to infection with Plasmodium, a genus of parasites that causes malaria in humans. Inside an Anopheles gambiae … |
Baltimore Sun |
Stem cells could boost this Maryland baby’s heart and chance for a normal life
Baltimore Sun Dr. Sunjay Kaushal, director of pediatric and adult congenital surgery at the University of Maryland and one of the nation’s foremost surgeons for hypoplastic left heart syndrome, said Autumn’s general health beyond the condition and her supportive … |
Technology Networks |
CRISPR Creates a Malaria-Resistant Mosquito
Technology Networks “Our study shows that we can use this new CRISPR/Cas9 gene-editing technology to render mosquitoes malaria-resistant by removing a so-called host factor gene,” says study senior author George Dimopoulos, PhD, professor in the Bloomberg School’s … |